Avalo Therapeutics' Item 1C disclosure describes its Information Security Program, governance (ISWG, Audit Committee oversight), NIST CSF-based controls, third-party MSSP monitoring, vendor risk assessments, and annual employee security awareness training including phishing simulations. The filing explicitly states the company has not identified any material cybersecurity incident to date. No breach is disclosed.